BACITRACIN ZINC AND POLYMYXIN B SULFATE- bacitracin zinc and polymyxin b sulfate ointment

Preferred Pharmaceuticals Inc.

-----

Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment, USP (Sterile)

Rx only

## **DESCRIPTION**

Bacitracin zinc and polymyxin B sulfate ophthalmic ointment, USP is a sterile antimicrobial ointment formulated for ophthalmic use.

Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of *Bacillus subtilis* var Tracy. It has a potency of not less than 40 bacitracin units/mg. The structural formula for bacitracin A is:

Polymyxin B sulfate is the sulfate salt of polymyxin  $B_1$  and  $B_2$ , which are produced by the growth of *Bacillus polymyxa* (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units/mg, calculated on an anhydrous basis. The structural formulae are:

**Each gram contains: Actives:** bacitracin zinc equal to 500 bacitracin units and polymyxin B sulfate equal to 10,000 polymyxin B units; **Inactives:** mineral oil and white petrolatum.

### CLINICAL PHARMACOLOGY

Polymyxin B sulfate attacks gram-negative bacilli, including virtually all strains of *Pseudomonas aeruginosa* and *Haemophilus influenzae* species.

Bacitracin is active against most gram-positive bacilli and cocci including hemolytic streptococci.

### INDICATIONS AND USAGE

For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate.

### CONTRAINDICATIONS

This product is contraindicated in those individuals who have shown hypersensitivity to any of its components.

## WARNINGS

Ophthalmic ointments may retard corneal healing.

# **PRECAUTIONS**

As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. Appropriate measures should be taken if this occurs.

### **ADVERSE REACTIONS**

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb

# Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

### DOSAGE AND ADMINISTRATION

Apply the ointment every 3 or 4 hours for 7 to 10 days, depending on the severity of the infection.

### FOR OPHTHALMIC USE ONLY

### **HOW SUPPLIED**

Bacitracin zinc and polymyxin B sulfate ophthalmic ointment, USP is available in tubes with an ophthalmic tip applicator in the following size:

NDC 68788-7599-3 - 3.5 g tube

# DO NOT USE IF CAP AND NECKRING ARE NOT INTACT.

# Storage:

Store between 15°C to 25°C (59°F to 77°F). **KEEP TIGHTLY CLOSED.** 

### KEEP OUT OF REACH OF CHILDREN.

# Distributed by:

Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA

# Manufactured by:

Bausch & Lomb Incorporated Tampa, FL 33637 USA

© 2022 Bausch & Lomb Incorporated or its affiliates

# Relabeled By: Preferred Pharmaceuticals Inc.

Revised: May 2022 9130704 (Folded) 9130604 (Flat)

### PRINCIPAL DISPLAY PANEL

**NDC** 68788-7599-3

Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment, USP (Sterile)

# FOR OPHTHALMIC USE ONLY

**Rx only** 

Net Wt. 3.5 g (1/8 oz)

**BAUSCH + LOMB** 

# Relabeled By: Preferred Pharmaceuticals Inc.

9733301 AB07534



# **BACITRACIN ZINC AND POLYMYXIN B SULFATE**

bacitracin zinc and polymyxin b sulfate ointment

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:68788-7599(NDC:24208- 555)
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety				
Ingredient Name	Basis of Strength	Strength		
BACITRACIN ZINC (UNII: 89Y4M234ES) (BACITRACIN - UNII:58H6RW052I)	BACITRACIN	500 [USP'U] in 1 g		
POLYMYXIN B SULFATE (UNII: 19371312D4) (POLYMYXIN B - UNII: J2VZ 07J96K)	POLYMYXIN B	10000 [USP'U] in 1 g		

Inactive Ingredients			
Ingredient Name	Strength		
PETROLATUM (UNII: 4T6H12BN9U)			
MINERAL OIL (UNII: T5L8T28FGP)			

Packaging			
# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:68788- 7599-3	1 in 1 CARTON	03/27/2020	
1	3.5 g in 1 TUBE; Type 0: Not a Combination Product		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA064046	03/27/2020	

# **Labeler -** Preferred Pharmaceuticals Inc. (791119022)

# **Registrant - Preferred Pharmaceuticals Inc. (791119022)**

Establishment				
Name	Address	ID/FEI	<b>Business Operations</b>	
Preferred Pharmaceuticals Inc.		791119022	RELABEL(68788-7599)	

Revised: 2/2024 Preferred Pharmaceuticals Inc.